| The Study Will Evaluate if Leuprolide Mesylate is Safe and Effective in the Treatment of Subjects With Advanced Prostate Carcinoma, When Administered as Two Injections Six Months Apart. (NCT06984159) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2022-07-12 |
| A Study of Neoadjuvant Hormone Therapy in Patient With Advanced Prostate Cancer Undergoing Radical Prostatectomy. (NCT03971110) | AstraZeneca | 2021-01-28 |
| Goserelin 10.8mg Injection in Treatment of Advanced Prostate Cancer (NCT03936218) | Eurofarma Laboratorios S.A. | 2020-09-30 |
| Whole Body Magnetic Resonance Imaging Study (NCT04117594) | Royal Marsden NHS Foundation Trust | 2019-10-09 |
| SRAM study_Postate Cancer (NCT03938649) | CCTU | 2019-05-15 |
| Evaluation of PSMA-based PET as an Imaging Biomarker in Prostate Cancer (NCT02420977) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-12-06 |
| TUPKRP Combined With MAB Therapy for LUTS/PCa (NCT03701659) | The Third Xiangya Hospital of Central South University | 2018-12-01 |
| Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer (NCT03651271) | Parker Institute for Cancer Immunotherapy | 2018-10-17 |
| Intermittent Androgen Deprivation Therapy for Stage IV Castration Sensitive Prostate Cancer (NCT03511196) | H. Lee Moffitt Cancer Center and Research Institute | 2018-09-17 |
| Study of HPN424 in Patients With Advanced Prostate Cancer (NCT03577028) | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2018-07-24 |
| Therapy Pathways in the Treatment of Hormone Naïve Prostate Cancer Patients With and Without Comorbidities Treated With Degarelix or Luteinizing-Hormone-Releasing-Hormone (LHRH) Agonists. (NCT02234089) | Ferring Pharmaceuticals | 2014-09-01 |
| PROSABI: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Abiraterone Acetate. (NCT02787837) | Centro Nacional de Investigaciones Oncologicas CARLOS III | 2014-05-01 |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. (NCT02362620) | Centro Nacional de Investigaciones Oncologicas CARLOS III | 2014-05-01 |
| Cabazitaxel and BKM120 in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel (NCT02035124) | SCRI Development Innovations, LLC | 2014-04-01 |
| A Registry of Sipuleucel-T Therapy in Men With Advanced Prostate Cancer (NCT01306890) | Dendreon | 2011-01-27 |
| Prostate Cancer, Androgen Deprivation Withdrawal and Intermittent Chemotherapy (NCT01224405) | University of Turin, Italy | 2010-04-01 |